HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 166 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $15,879,949 | +40.9% | 303,284 | +9.5% | 0.01% | +40.0% |
Q1 2024 | $11,271,288 | +10.1% | 277,072 | +0.1% | 0.01% | 0.0% |
Q4 2023 | $10,234,297 | -2.7% | 276,902 | +0.6% | 0.01% | -16.7% |
Q3 2023 | $10,513,977 | -32.1% | 275,235 | -35.9% | 0.01% | -33.3% |
Q2 2023 | $15,485,536 | -6.2% | 429,319 | -0.7% | 0.01% | -10.0% |
Q1 2023 | $16,509,880 | +66461.4% | 432,309 | -0.8% | 0.01% | -41.2% |
Q4 2022 | $24,804 | -99.9% | 435,917 | -36.7% | 0.02% | -15.0% |
Q3 2022 | $27,243,000 | -39.0% | 689,000 | -32.1% | 0.02% | -37.5% |
Q2 2022 | $44,673,000 | +19.0% | 1,015,289 | +7.8% | 0.03% | +45.5% |
Q1 2022 | $37,548,000 | -0.9% | 941,514 | -0.1% | 0.02% | +4.8% |
Q4 2021 | $37,907,000 | -7.3% | 942,730 | -6.2% | 0.02% | -16.0% |
Q3 2021 | $40,901,000 | -2.5% | 1,005,438 | +8.8% | 0.02% | -3.8% |
Q2 2021 | $41,946,000 | +12.0% | 923,714 | +2.9% | 0.03% | 0.0% |
Q1 2021 | $37,441,000 | -3.7% | 898,077 | -1.4% | 0.03% | -10.3% |
Q4 2020 | $38,897,000 | +55.1% | 910,715 | -4.6% | 0.03% | +31.8% |
Q3 2020 | $25,075,000 | -11.5% | 954,157 | -9.7% | 0.02% | -21.4% |
Q2 2020 | $28,329,000 | +43.9% | 1,056,671 | -3.5% | 0.03% | +16.7% |
Q1 2020 | $19,693,000 | -6.1% | 1,094,671 | -7.4% | 0.02% | +14.3% |
Q4 2019 | $20,969,000 | +15.6% | 1,182,663 | +1.1% | 0.02% | +5.0% |
Q3 2019 | $18,145,000 | -9.2% | 1,169,916 | +0.6% | 0.02% | -9.1% |
Q2 2019 | $19,983,000 | -28.2% | 1,163,160 | -35.7% | 0.02% | +22.2% |
Q1 2019 | $27,829,000 | +119.7% | 1,807,609 | +108.8% | 0.02% | +5.9% |
Q4 2018 | $12,668,000 | +55.9% | 865,919 | +93.6% | 0.02% | +70.0% |
Q3 2018 | $8,128,000 | +6.2% | 447,338 | -1.4% | 0.01% | 0.0% |
Q2 2018 | $7,653,000 | -21.6% | 453,652 | -8.9% | 0.01% | -23.1% |
Q1 2018 | $9,756,000 | -14.1% | 498,014 | -11.1% | 0.01% | -13.3% |
Q4 2017 | $11,353,000 | +12.1% | 560,373 | -3.9% | 0.02% | +7.1% |
Q3 2017 | $10,131,000 | +28.7% | 583,221 | -5.0% | 0.01% | +16.7% |
Q2 2017 | $7,872,000 | -1.5% | 614,021 | -0.4% | 0.01% | -7.7% |
Q1 2017 | $7,990,000 | +22.0% | 616,511 | -7.0% | 0.01% | +18.2% |
Q4 2016 | $6,549,000 | -25.2% | 662,811 | -8.6% | 0.01% | -31.2% |
Q3 2016 | $8,758,000 | +33.0% | 725,011 | 0.0% | 0.02% | +33.3% |
Q2 2016 | $6,583,000 | -22.3% | 725,011 | +2.4% | 0.01% | -25.0% |
Q1 2016 | $8,472,000 | -30.9% | 707,780 | 0.0% | 0.02% | -33.3% |
Q4 2015 | $12,266,000 | +29.0% | 707,780 | 0.0% | 0.02% | +20.0% |
Q3 2015 | $9,505,000 | -43.2% | 707,780 | -4.5% | 0.02% | -39.4% |
Q2 2015 | $16,731,000 | +53.6% | 740,955 | -2.9% | 0.03% | +50.0% |
Q1 2015 | $10,892,000 | +48.0% | 762,780 | 0.0% | 0.02% | +46.7% |
Q4 2014 | $7,361,000 | +6.1% | 762,780 | 0.0% | 0.02% | 0.0% |
Q3 2014 | $6,941,000 | -11.3% | 762,780 | -3.7% | 0.02% | -6.2% |
Q2 2014 | $7,823,000 | – | 791,760 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 14,092,771 | $206,177,000 | 28.12% |
BB BIOTECH AG | 8,322,860 | $121,763,000 | 3.90% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 398,633 | $4,579,000 | 2.84% |
DOHENY ASSET MANAGEMENT /CA | 227,193 | $3,324,000 | 2.43% |
SNYDER CAPITAL MANAGEMENT L P | 2,833,759 | $41,458,000 | 2.24% |
First Light Asset Management, LLC | 938,399 | $13,729,000 | 2.19% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,027,164 | $132,067,000 | 1.77% |
Taylor Wealth Management Partners | 204,277 | $2,989,000 | 1.72% |
Sterling Global Strategies LLC | 22,000 | $321,860,000 | 1.63% |
Granite Investment Partners, LLC | 988,939 | $14,468,000 | 1.06% |